• レポートコード:MRC2403B283 • 出版社/出版日:Transparency Market Research / 2023年12月 • レポート形態:英文、PDF、192ページ • 納品方法:受注後3営業日 • 産業分類:医療 |
Single User | ¥869,250 (USD5,795) | ▷ お問い合わせ |
Multi User | ¥1,319,250 (USD8,795) | ▷ お問い合わせ |
Corporate License | ¥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
放射線量管理市場 - レポートの範囲TMR社の調査レポート「世界の放射線量管理市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会を調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界の放射線量管理市場の収益を提供しています。また、2023年から2031年までの世界の放射線量管理市場の複合年間成長率(CAGR %)も掲載しています。 本レポートは広範な調査を経て作成されました。主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連文書などを参照し、放射線量管理市場を把握した。 二次調査には、インターネット情報源、政府機関の統計データ、ウェブサイト、業界団体も含まれます。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の放射線量管理市場の様々な属性を調査しました。 本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、世界の放射線量管理市場における競争ダイナミクスの変化にも光を当てています。これらは、既存の市場関係者だけでなく、世界の放射線量管理市場への参入に関心のある企業にとっても貴重なツールとなります。 本レポートでは、世界の放射線量管理市場の競争状況について掘り下げています。世界の放射線量管理市場で事業を展開する主要企業が特定され、それぞれの企業が様々な属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の放射線量管理市場におけるプレイヤーの属性です。 放射線量管理の世界市場レポートが回答した主な質問 - 予測期間中の全地域における放射線量管理の売上/収益は? - 世界の放射線量管理市場におけるビジネスチャンスは? - 市場の主な促進要因、阻害要因、機会、脅威は何か? - 予測期間中に最も速いCAGRで拡大する地域市場はどこか? - 2031年に世界で最も高い収益を上げると予測されるセグメントは? - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントは? - 世界市場で事業を展開する各企業の市場ポジションは? 放射線量管理市場 - 調査目的と調査アプローチ 世界の放射線量管理市場に関する包括的なレポートは、概要から始まり、調査範囲と目的が続きます。本レポートでは、本調査の目的、市場で事業を展開する主要ベンダーや流通業者、製品承認のための規制シナリオについて詳細に解説しています。 本レポートは、読みやすさを考慮し、各セクションを章ごとに分割したレイアウトになっています。本レポートは、グラフや表が適切に散りばめられた網羅的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えます。また、過去と予測期間末の主要セグメントの市場シェアの比較も可能です。 本レポートでは、世界の放射線量管理市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントにおける市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界の放射線量管理市場への投資について、十分な情報に基づいたビジネス上の意思決定を行うことができます。 |
1. 序論
2. 仮定・調査手法
3. エグゼクティブサマリー:世界の放射線量管理市場
4. 市場概要
5. 主要インサイト
6. 世界の放射線量管理市場分析・予測:製品&サービス別
7. 世界の放射線量管理市場分析・予測:モダリティ別
8. 世界の放射線量管理市場分析・予測:用途別
9. 世界の放射線量管理市場分析・予測:エンドユーザー別
10. 世界の放射線量管理市場分析・予測:地域別
11. 北米の放射線量管理市場分析・予測
12. ヨーロッパの放射線量管理市場分析・予測
13. アジア太平洋の放射線量管理市場分析・予測
14. 中南米の放射線量管理市場分析・予測
15. 中東/アフリカの放射線量管理市場分析・予測
16. 競争状況
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiation Dose Management Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Radiation Dose Management Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Radiation Dose Management Market Analysis and Forecast, by Product and Services
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product and Services, 2017–2031
6.3.1. Software
6.3.1.1. Integrated Solution
6.3.1.2. Standalone Solution
6.3.2. Services
6.4. Market Attractiveness, by Product and Services
7. Global Radiation Dose Management Market Analysis and Forecast, by Modality
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Modality, 2017–2031
7.3.1. Computed Tomography
7.3.2. Radiography and Mammography
7.3.3. Fluoroscopy and Interventional Imaging
7.3.4. Nuclear Medicine Scan
7.3.5. Others
7.3.6. 7.4 Market Attractiveness, by Modality
8. Global Radiation Dose Management Market Analysis and Forecast, by Application
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017–2031
8.3.1. Oncology
8.3.2. Cardiology
8.3.3. Orthopedic
8.3.4. Others
8.4. Market Attractiveness, by Application
9. Global Radiation Dose Management Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Hospitals
9.3.2. Ambulatory Care Settings
9.3.3. Research Organizations
9.3.4. Others
9.4. Market Attractiveness, by End-user
10. Global Radiation Dose Management Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Radiation Dose Management Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product and Services, 2017–2031
11.2.1. Software
11.2.1.1. Integrated Solution
11.2.1.2. Standalone Solution
11.2.2. Services
11.3. Market Attractiveness, by Product and Services
11.4. Market Value Forecast, by Modality, 2017–2031
11.4.1. Computed Tomography
11.4.2. Radiography and Mammography
11.4.3. Fluoroscopy and Interventional Imaging
11.4.4. Nuclear Medicine Scan
11.4.5. Others
11.5. Market Attractiveness, by Modality
11.6. Market Value Forecast, by Application, 2017–2031
11.6.1. Oncology
11.6.2. Cardiology
11.6.3. Orthopedic
11.6.4. Others
11.7. Market Attractiveness, by Application
11.8. Market Value Forecast, by End-user, 2017–2031
11.8.1. Hospitals
11.8.2. Ambulatory Care Settings
11.8.3. Research Organizations
11.8.4. Others
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Product and Services
11.11.2. By Modality
11.11.3. By Application
11.11.4. By End-user
11.11.5. By Country
12. Europe Radiation Dose Management Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product and Services, 2017–2031
12.2.1. Software
12.2.1.1. Integrated Solution
12.2.1.2. Standalone Solution
12.2.2. Services
12.3. Market Attractiveness, by Product and Services
12.4. Market Value Forecast, by Modality, 2017–2031
12.4.1. Computed Tomography
12.4.2. Radiography and Mammography
12.4.3. Fluoroscopy and Interventional Imaging
12.4.4. Nuclear Medicine Scan
12.4.5. Others
12.5. Market Attractiveness, by Modality
12.6. Market Value Forecast, by Application, 2017–2031
12.6.1. Oncology
12.6.2. Cardiology
12.6.3. Orthopedic
12.6.4. Others
12.7. Market Attractiveness, by Application
12.8. Market Value Forecast, by End-user, 2017–2031
12.8.1. Hospitals
12.8.2. Ambulatory Care Settings
12.8.3. Research Organizations
12.8.4. Others
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Product and Services
12.11.2. By Modality
12.11.3. By Application
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Radiation Dose Management Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product and Services, 2017–2031
13.2.1. Software
13.2.1.1. Integrated Solution
13.2.1.2. Standalone Solution
13.2.2. Services
13.3. Market Attractiveness, by Product and Services
13.4. Market Value Forecast, by Modality, 2017–2031
13.4.1. Computed Tomography
13.4.2. Radiography and Mammography
13.4.3. Fluoroscopy and Interventional Imaging
13.4.4. Nuclear Medicine Scan
13.4.5. Others
13.5. Market Attractiveness, by Modality
13.6. Market Value Forecast, by Application, 2017–2031
13.6.1. Oncology
13.6.2. Cardiology
13.6.3. Orthopedic
13.6.4. Others
13.7. Market Attractiveness, by Application
13.8. Market Value Forecast, by End-user, 2017–2031
13.8.1. Hospitals
13.8.2. Ambulatory Care Settings
13.8.3. Research Organizations
13.8.4. Others
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Product and Services
13.11.2. By Modality
13.11.3. By Application
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Radiation Dose Management Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product and Services, 2017–2031
14.2.1. Software
14.2.1.1. Integrated Solution
14.2.1.2. Standalone Solution
14.2.2. Services
14.3. Market Attractiveness, by Product and Services
14.4. Market Value Forecast, by Modality, 2017–2031
14.4.1. Computed Tomography
14.4.2. Radiography and Mammography
14.4.3. Fluoroscopy and Interventional Imaging
14.4.4. Nuclear Medicine Scan
14.4.5. Others
14.5. Market Attractiveness, by Modality
14.6. Market Value Forecast, by Application, 2017–2031
14.6.1. Oncology
14.6.2. Cardiology
14.6.3. Orthopedic
14.6.4. Others
14.7. Market Attractiveness, by Application
14.8. Market Value Forecast, by End-user, 2017–2031
14.8.1. Hospitals
14.8.2. Ambulatory Care Settings
14.8.3. Research Organizations
14.8.4. Others
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Product and Services
14.11.2. By Modality
14.11.3. By Application
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Radiation Dose Management Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product and Services, 2017–2031
15.2.1. Software
15.2.1.1. Integrated Solution
15.2.1.2. Standalone Solution
15.2.2. Services
15.3. Market Attractiveness, by Product and Services
15.4. Market Value Forecast, by Modality, 2017–2031
15.4.1. Computed Tomography
15.4.2. Radiography and Mammography
15.4.3. Fluoroscopy and Interventional Imaging
15.4.4. Nuclear Medicine Scan
15.4.5. Others
15.5. Market Attractiveness, by Modality
15.6. Market Value Forecast, by Application, 2017–2031
15.6.1. Oncology
15.6.2. Cardiology
15.6.3. Orthopedic
15.6.4. Others
15.7. Market Attractiveness, by Application
15.8. Market Value Forecast, by End-user, 2017–2031
15.8.1. Hospitals
15.8.2. Ambulatory Care Settings
15.8.3. Research Organizations
15.8.4. Others
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Product and Services
15.11.2. By Modality
15.11.3. By Application
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player -Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Landauer
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Agfa-Gevaert Group
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Sectra AB
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. INFINITT Healthcare Co. Ltd.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Bayer AG
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. PACSHealth, LLC
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Koninklijke Philips N.V.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. GE Healthcare
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Thermo Fisher Scientific, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Medsquare SAS
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Siemens
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Fujifilm Holdings Corporation
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. QAELUM NV
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview